Synexus, a European recruitment and trial management firm, announced its acquisition of Polish CRO Osteomed. The move reaffirms Synexus' interest in Poland, a country where it has quadrupled its capacity in the last two years.
Poland is emerging as a new power player in global outsourcing, as the Synexus' release shows. Analysts predict that the country's clinical trials market will reach $323 million by 2015, thanks to perks like significant cost advantages, a motivated patient population and strong trial data quality. Synexus CEO Christophe Berthoux acknowledges that the company is eyeing Poland as a gateway to future business growth in Central and Eastern Europe.
"We have had a well-established presence in Poland for a number of years but felt that now was the time to further strengthen this, both in recognition of the area as well as in support of our business growth," Berthoux said in a statement. "The acquisition of Osteomed will enhance our capacity, bring us scientific expertise and experience in the field of bone diseases and access to an extensive patient database."
With the acquisition, Osteomed owners Andrzej Sawicki and Piotr Sawicki will obtain senior positions at Synexus. The cost of the acquisition has yet to be disclosed.
- check out the story from PharmaTimes
- read a release on the acquisition from Synexus